141 unknown. 141 Phase 2, 30 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 141 | Unknown 141 |
| Phase 1 | 30 | Unknown 30 |
| Phase 3 | 4 | Unknown 4 |
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy Vorolanib Tablets, Sintilimab Injection - Renal Cell Carcinoma, Immunotherapy | Phase 2 | Unknown | Hao Zeng | 67 | 2024-08-01 | 2024-07-26 |
| Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors TT-00420 + Toripalimab - Clear Cell Renal Carcinoma, Urothelial Carcinoma | Phase 1 / Phase 2 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 42 | 2024-02-01 | 2024-01-24 |
| Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma Pucotenlimab Combined With Lenvatinib - Renal Cell Carcinoma | Phase 2 | Unknown | Sun Yat-sen University | 47 | 2023-11-11 | 2023-11-13 |
| Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer Pseudomonas aeruginosa - Bladder Cancer | Phase 2 | Unknown | Qilu Hospital of Shandong University | 63 | 2023-10-01 | 2023-09-21 |
| RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression RC48, Tislelizumab - Non-Muscle Invasive Bladder Cancer, HER2 | Phase 2 | Unknown | RenJi Hospital | 20 | 2023-08-05 | 2023-08-31 |
| 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses 68Ga-NY104 PET/CT - Clear Cell Renal Cell Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 63 | 2023-08-01 | 2023-07-13 |
| 68Ga-NY104 PET/CT in Patients With Metastatic Clear Cell Renal Cell Carcinoma 68Ga-NY104 PET/CT - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 39 | 2023-08-01 | 2023-07-24 |
| RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer RC48-ADC - Non-muscle Invasive Bladder Cancer | Phase 2 | Unknown | West China Hospital | 77 | 2023-08-01 | 2023-08-18 |
| 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion 68Ga-NY104 PET/CT - Clear Cell Renal Cell Carcinoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 40 | 2023-08-01 | 2023-07-13 |
| Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma Sodium Pentaborate - Renal Cell Carcinoma | Phase 1 / Phase 2 | Unknown | Tabriz University of Medical Sciences | 30 | 2023-05-22 | 2023-04-04 |
| Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy - Urinary Bladder Neoplasms | Phase 2 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 65 | 2023-02-01 | 2022-12-28 |
| A Study of HB0025 Injection in Patients With Advanced Renal Cancer HB0025 - Renal Cancer | Phase 2 | Unknown | Huabo Biopharm Co., Ltd. | 100 | 2023-01-30 | 2024-01-24 |
| SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy Pembrolizumab Injection [Keytruda], Salvage Radiation Therapy (SRT) - Urologic Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate | Phase 2 | Unknown | Prof. Dr. med. Christian Gratzke | 49 | 2022-10-20 | 2023-03-01 |
| Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer Cadonilimab - Bladder Cancer | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 20 | 2022-10-10 | 2023-08-24 |
| A Study of Oncobax®-AK in Patients With Advanced Solid Tumors Live Bacterial Product - Akkermansia muciniphila - Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung | Phase 2 | Unknown | EverImmune | 122 | 2022-10-01 | 2023-05-19 |
| Immunological Variables Associated to ICI Toxicity in Cancer Patients Checkpoint Blockade, Immune - Breast Cancer, Melanoma | Phase 2 | Unknown | Jules Bordet Institute | 441 | 2022-09-01 | 2023-03-08 |
| Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer H101, Camrelizumab - Bladder Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 25 | 2022-08-26 | 2022-10-04 |
| OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer OH2 injection - Non-muscle-invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Binhui Biopharmaceutical Co., Ltd. | 30 | 2022-07-11 | 2024-08-12 |
| Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC). Atezolizumab - Squamous Cell Carcinoma, Urinary Tract Cancer | Phase 2 | Unknown | University Hospital Southampton NHS Foundation Trust | 36 | 2022-05-30 | 2022-10-03 |
| REduced Frequency ImmuNE Checkpoint Inhibition in Cancers Nivolumab, Pembrolizumab - Renal Cell Carcinoma, Melanoma | Phase 2 | Unknown | University College, London | 160 | 2022-05-26 | 2022-09-21 |
Showing 20 of 141. Sign in to see all of them.
Carcinoma, Renal Cell (84) · Urinary Bladder Neoplasms (43) · Kidney Neoplasms (31) · Carcinoma, Non-Small-Cell Lung (10) · Melanoma (9) · Carcinoma, Transitional Cell (7) · Non-Muscle Invasive Bladder Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Hepatocellular (6) · Stomach Neoplasms (6) · Colorectal Neoplasms (5) · Neoplasm Metastasis (5) · Neoplasms (5) · Wilms Tumor (5)
Female Urogenital Diseases (141) · Female Urogenital Diseases and Pregnancy Complications (141) · Male Urogenital Diseases (141) · Neoplasms by Site (141) · Urogenital Diseases (141) · Urologic Diseases (141) · Urogenital Neoplasms (138) · Neoplasms (136) · Neoplasms by Histologic Type (100) · Neoplasms, Glandular and Epithelial (96) · Kidney Diseases (94) · Carcinoma (93) · Adenocarcinoma (84) · Kidney Neoplasms (63)
Sunitinib (12) · aldesleukin (10) · Nivolumab (8) · pembrolizumab (8) · Bevacizumab (7) · Axitinib (5) · durvalumab (5) · Gemcitabine (4) · Sorafenib (4) · atezolizumab (4) · sintilimab (4) · Chemotherapy, Adjuvant (3) · Cyclophosphamide (3) · Electroporation (3) · Interferon-alpha (3)
Peking Union Medical College Hospital (4) · West China Hospital (4) · Blumenthal Cancer Center at Carolinas Medical Center (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · RenJi Hospital (3) · Sun Yat-sen University (3) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · Tianjin Medical University Second Hospital (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Asan Medical Center (2) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2) · Cancer Biotherapy Research Group (2) · Hellenic GenitoUrinary Cancer Group (2) · Peking University Cancer Hospital & Institute (2) · Queen Mary University of London (2)
China (41) · United States (26) · United Kingdom (12) · Italy (7) · Netherlands (6) · Australia (5) · South Korea (5) · France (4) · Germany (4) · Spain (4) · Belgium (3) · Canada (3) · Denmark (3) · Greece (2) · Switzerland (2)
Li Huo, MD (3) · Richard L. White, MD (3) · Hao Zeng (2) · John P. Hanson, MD (2) · Jun Guo, MD,PHD (2) · Adriaan D. Bins, MD PhD (1) · Adrian L. Harris, MD (1) · Ahmed M. Asmy, MD (1) · Alexander Prokhorov, Dr (1) · Ali R Ayder, MD (1) · Andrei Hancharou (1) · Arnulf Stenzl, Prof. (1) · Axel Bex, MD (1)
PMID 10673991, PMID 16773629, PMID 17409436, PMID 17452976, PMID 17997439, PMID 19097774, PMID 21277078, PMID 21555688, PMID 22045104, PMID 22228449, PMID 22461641, PMID 23747347, PMID 23770567, PMID 24242861, PMID 24472710, PMID 24476821, PMID 24668644, PMID 24720900, PMID 25428503, PMID 25720673, PMID 25747273, PMID 25886058, PMID 25902855, PMID 26228759, PMID 26487582, PMID 26871284, PMID 27140411, PMID 27269937, PMID 27324051, PMID 27345655, PMID 27726966, PMID 28078238, PMID 28209559, PMID 28271869, PMID 28481359, PMID 28817753, PMID 28911922, PMID 29392960, PMID 29650037, PMID 31023100, PMID 31900121, PMID 32124514, PMID 32457838, PMID 34006499, PMID 34103518, PMID 34327591, PMID 34732486, PMID 34965951, PMID 34998048, PMID 35017154
2016 (2), 2018 (2), 2015 (1), 2017 (1), 2019 (1)